fbpx

Day

February 3, 2020
CAMBRIDGE, Mass., Jan. 31, 2020 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that on January 31, 2020 the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards...

News

Seven research institutions receive DKK 20 million for coronavirus research
1. April 2020
How we handle changes to research projects in light of the coronavirus pandemic
31. March 2020
Lundbeck Foundation gives its first coronavirus grant to trial with a known drug
26. March 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge